Table of Contents
1. Executive Summary
2. Market Background and Classifications
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. Market Trends and Forecast Analysis from 2014 to 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Gene Therapy Market Trends and Forecast
3.3: Global Gene Therapy Market by Gene Type
3.3.1: Antigen
3.3.2: Cytokine
3.3.3: Tumor Suppressor
3.3.4: Suicide
3.3.5: Deficiency
3.3.6: Growth Factors
3.3.7: Receptors
3.3.8: Others
3.4. Global Gene Therapy Market by Application
3.4.1: Oncological Disorders
3.4.2: Rare Diseases
3.4.3: Cardiovascular Diseases
3.4.4: Neurological Disorders
3.4.5: Infectious Disease
3.4.6: Other Diseases
3.5. Global Gene Therapy Market by Vector
3.5.1: Non-Viral Vectors
3.5.1.1: Oligonucleotides
3.5.1.2: Other Non-Viral Vectors
3.5.2: Viral Vectors
3.5.2.1: Retroviral Vectors
3.5.2.2: Adeno-Associated Virus Vectors
3.5.2.3: Other Viral Vectors
3.6. Global Gene Therapy Market by Indication
3.6.1: Neurological Diseases
3.6.2: Cancer
3.6.3: Hepatological Diseases
3.6.4: Duchenne Muscular Dystrophy
3.6.5: Other Indications
3.7. Global Gene Therapy Market by Delivery Method
3.7.1: In Vivo Gene Therapy
3.7.2: Ex Vivo Gene Therapy
4. Market Trends and Forecast Analysis by Region
4.1: Global Gene Therapy Market by Region
4.2: North American Gene Therapy Market
4.2.1: Market by Gene Type: Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others
4.2.2: Market byApplication: Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases
4.2.3: Market by Vector: Non-Viral Vectors (Oligonucleotides and Other Non-Viral Vectors) and Viral Vectors (Retroviral Vectors, Adeno-Associated Virus Vectors, and Other Viral Vectors
4.2.4: Market by Indication: Neurological Diseases, Cancer, Hepatological Diseases, Duchenne Muscular Dystrophy, and Other Indications
4.2.5: Market by Delivery Method: In Vivo Gene Therapy and Ex Vivo Gene Therapy
4.2.6: The United States Gene Therapy Market
4.2.7: The Canadian Gene Therapy Market
4.2.8: The Mexican Gene Therapy Market
4.3. European Gene Therapy Market
4.3.1: Market by Gene Type: Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others
4.3.2: Market by Application: Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases
4.3.3: Market by Vector: Non-Viral Vectors (Oligonucleotides and Other Non-Viral Vectors) and Viral Vectors (Retroviral Vectors, Adeno-Associated Virus Vectors, and Other Viral Vectors
4.3.4: Market by Indication: Neurological Diseases, Cancer, Hepatological Diseases, Duchenne Muscular Dystrophy, and Other Indications
4.3.5: Market by Delivery Method: In Vivo Gene Therapy and Ex Vivo Gene Therapy
4.3.6: The Gene Therapy Market of United Kingdom
4.3.7: The German Gene Therapy Market
4.3.8: The French Gene Therapy Market
4.4. APAC Gene Therapy Market
4.4.1: Market by Gene Type: Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others
4.4.2: Market byApplication: Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases
4.4.3: Market by Vector: Non-Viral Vectors (Oligonucleotides and Other Non-Viral Vectors) and Viral Vectors (Retroviral Vectors, Adeno-Associated Virus Vectors, and Other Viral Vectors
4.4.4: Market by Indication: Neurological Diseases, Cancer, Hepatological Diseases, Duchenne Muscular Dystrophy, and Other Indications
4.4.5: Market by Delivery Method: In Vivo Gene Therapy and Ex Vivo Gene Therapy
4.4.6: The Chinese Gene Therapy Market
4.4.7: The Indian Gene Therapy Market
4.4.8: The Japanese Gene Therapy Market
4.5: ROW Gene Therapy Market
4.5.1: Market by Gene Type: Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others
4.5.2: Market by Application: Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases
4.5.3: Market by Vector: Non-Viral Vectors (Oligonucleotides and Other Non-Viral Vectors) and Viral Vectors (Retroviral Vectors, Adeno-Associated Virus Vectors, and Other Viral Vectors
4.5.4: Market by Indication: Neurological Diseases, Cancer, Hepatological Diseases, Duchenne Muscular Dystrophy, and Other Indications
4.5.5: Market by Delivery Method: In Vivo Gene Therapy and Ex Vivo Gene Therapy
4.5.6: Brazilian Gene Therapy Market
5. Competitor Analysis
5.1: Market Share Analysis
5.2: Product Portfolio Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. Cost Structure Analysis
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. Growth Opportunities and Strategic Analysis
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Gene Therapy Market by Gene Type
7.1.2: Growth Opportunities for the Global Gene Therapy Market by Application
7.1.3: Growth Opportunities for the Global Gene Therapy Market by Vector
7.1.4: Growth Opportunities for the Global Gene Therapy Market by Indication
7.1.5: Growth Opportunities for the Global Gene Therapy Market by Delivery Method
7.1.6: Growth Opportunities for the Global Gene Therapy Market by Region
7.2: Emerging Trends in the Global Gene Therapy Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Gene Therapy Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Gene Therapy Market
7.3.4: Certification and Licensing
8. Company Profiles of Leading Players
8.1: Biogen
8.2: Novartis AG
8.3: Gilead Sciences, Inc.
8.4: Spark Therapeutics, Inc.
8.5: MolMed S.p.A
8.6: Orchard Therapeutics plc.
8.7: SIBIONO
8.8: Shanghai Sunway Biotech Co., Ltd.
8.9: Bluebird Bio, Inc.
8.10: Human Stem Cells Institute